Semaglutide
GLP-1 receptor agonist for metabolic research and weight regulation.
Tap a strength to switch — price, image & stock update automatically
Key Benefits
activates receptors in the pancreas, brain, and gut simultaneously for a coordinated multi-organ metabolic response
reduces hunger signals in the hypothalamus, leading to 10–15% body weight reduction in clinical trials
stimulates insulin release in response to meals while suppressing glucagon, improving blood sugar control
LEADER trial demonstrated a 26% reduction in cardiovascular death, making it a key compound for cardiometabolic studies
Active Signaling Pathway
Semaglutide activates GLP-1 receptors simultaneously in the hypothalamus (appetite suppression), gut (gastric emptying), and pancreas (insulin secretion), creating a coordinated multi-organ metabolic response.
Investigated Pathways
Proposed Mechanism
Semaglutide is a 94% homologous analog of human GLP-1 with a C18 fatty diacid chain attached via a linker to lysine at position 26. This modification enables albumin binding, extending the half-life to ~7 days. It activates GLP-1 receptors in the pancreas (insulin secretion), hypothalamus (appetite suppression), and gut (gastric emptying delay), creating a multi-organ metabolic effect.
Research Highlights
- SUSTAIN and STEP trial programs demonstrated 10–15% body weight reduction at 1 mg/week and up to 15% at 2.4 mg/week
- LEADER trial showed 26% reduction in cardiovascular death in T2D patients with established CVD
- Emerging research shows GLP-1 receptor expression in the brain — semaglutide may reduce neuroinflammation and have neuroprotective effects
- 2023 SELECT trial: 20% reduction in major adverse cardiovascular events in non-diabetic obese patients
Evidence is primarily from in vitro cell studies and animal models. Human data is limited or absent.
For laboratory research only
All Research Systems →Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
For research use only — not for human consumption. No treatment claims.
Full Research Hub →Recommended Stacks
Semaglutide is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
Aesthetic Fat Loss Protocol
Targeted lipolysis + systemic fat metabolism + GLP-1 appetite control for comprehensive body recomposition.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 15mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
Semaglutide is a 94% homologous analog of human GLP-1 with a C18 fatty diacid chain attached via a linker to lysine at position 26. This modification enables albumin binding, extending the half-life to ~7 days. It activates GLP-1 receptors in the pancreas (insulin secretion), hypothalamus (appetite suppression), and gut (gastric emptying delay), creating a multi-organ metabolic effect.
Clinical Context
Semaglutide is one of the most extensively studied peptides in modern medicine, with over 40,000 patients enrolled in its clinical trial program. Its weekly dosing schedule and robust efficacy data make it a gold standard reference compound for GLP-1 receptor agonist research. The 2.4 mg/week dose (Wegovy) is FDA-approved for chronic weight management.
Research Highlights
- SUSTAIN and STEP trial programs demonstrated 10–15% body weight reduction at 1 mg/week and up to 15% at 2.4 mg/week
- LEADER trial showed 26% reduction in cardiovascular death in T2D patients with established CVD
- Emerging research shows GLP-1 receptor expression in the brain — semaglutide may reduce neuroinflammation and have neuroprotective effects
- 2023 SELECT trial: 20% reduction in major adverse cardiovascular events in non-diabetic obese patients
Storage & Reconstitution
Key Studies
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH et al.
Semaglutide 2.4 mg/week produced 14.9% mean body weight reduction vs 2.4% placebo over 68 weeks in adults with obesity.
PubMed →Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Marso SP et al.
Semaglutide reduced major adverse cardiovascular events by 26% vs placebo in high-risk T2D patients.
PubMed →Semaglutide 2.4 mg for the Treatment of Obesity (STEP 5)
Davies M et al.
Two-year STEP 5 data confirmed durable 15.2% weight loss with continued semaglutide treatment.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Activates cAMP/PKA signaling in pancreatic β-cells, hypothalamus, and gut
Reduces hunger signaling via arcuate nucleus GLP-1R activation
Glucose-dependent insulin secretion and glucagon suppression
Delays gastric emptying, prolonging satiety and reducing postprandial glucose spikes
Side Effects & Adverse Events
- Nausea (44%)
- Vomiting (24%)
- Diarrhea (30%)
- Constipation (24%)
- Injection site reactions
- Fatigue
- Dizziness
- Abdominal pain
- Pancreatitis (rare)
- Gallbladder disease including cholelithiasis
- Thyroid C-cell tumors (rodent data — human relevance unclear)
Contraindications & Interactions
Synergistic Compounds
CagriSema combination (semaglutide + cagrilintide) shows additive weight loss up to 25% — complementary GLP-1 and amylin receptor mechanisms.
Semaglutide 2.4 mg + Cagrilintide 2.4 mg, both once weekly SubQ, titrate each independently.
View Compound →Lipo-C provides B12 repletion and lipotropic support to counter fatigue and hepatic fat mobilization during GLP-1 caloric restriction.
Lipo-C 1 mL IM 2–3× per week alongside weekly semaglutide injection.
View Compound →For researchers escalating from GLP-1 monotherapy to dual GIP/GLP-1 agonism for superior weight loss outcomes.
Transition from semaglutide to tirzepatide after 12+ weeks; allow 2-week washout or direct switch.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States